Skip to content
Menu

Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $1050

Benzinga Newsdesk 3 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.

Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.

Read at benzinga.com